logo
A professor had a $2.4m grant to study Black maternal health. Then Trump was elected

A professor had a $2.4m grant to study Black maternal health. Then Trump was elected

Yahoo2 days ago
Jaime Slaughter-Acey was in a state of shock and anger when she learned that her National Institutes of Health (NIH)-funded study on birth outcomes in Black families was cancelled this spring. The University of North Carolina at Chapel Hill associate professor in epidemiology said that she felt like 'the rug was pulled out from under us' when the university called her to share the news. The termination notice said that the study no longer met the agency's priorities and didn't promise to increase life expectancy.
'It was heartbreaking,' Slaughter-Acey told the Guardian, 'and honestly, infuriating given the high rates of maternal and infant mortality in this country.'
The cancellation came as the Trump administration terminated 1,902 NIH grants totalling more than $4.4bn between his January inauguration and the end of July, according to Grant Witness data. NIH followed guidance from the so-called 'department of government efficiency' (Doge) and Trump's executive orders to cut costs. Additionally, in April, the Trump administration let go of a majority of the staff at the federal Division of Reproductive Health, a Centers for Disease Control and Prevention (CDC) office that collects data on maternal experiences. It also surveils pregnancy-related deaths in an effort to reduce infant mortality and improve health outcomes for mothers and their children.
Related: 'A scary time to be a scientist': how medical research cuts will hurt the maternal mortality crisis
Slaughter-Acey's several-year study funded by a more than $2.4m NIH grant aimed to look at how social and biological factors affect outcomes for more than 500 Black women in Detroit. The grant termination froze the team's more than $581,000 remaining funding. Through blood samples and surveys of Black mothers and grandmothers, Slaughter-Acey and her team aimed to understand if social environments accelerated how bodies physiologically age, otherwise known as biological ageing, which may lead to adverse pregnancy outcomes for Black women. She said that the research is 'designed to tell us how social environment and the pathways that social environment affects us physiologically, to then increase this risk that Black moms and Black babies have with respect to pregnancy'.
While most studies that look at racism only focus on one point in time, Slaughter-Acey said that hers was 'the first study to comprehensively examine how exposure to structural, cultural and intergenerational racism throughout a Black woman's life impacts her epigenome and her child's birth outcomes.' It was also innovative because Black women are underrepresented in epigenomic studies, a field where researchers look at how environment and behavior impacts a person's genes, said Slaughter-Acey, due to medical mistrust and experiences of racism in the healthcare system.
'When science is silenced, communities suffer'
The NIH-grant cancellation in late March followed the release of data from the CDC revealing that Black women were the only race or ethnic group who didn't experience a decline in deaths from pregnancy related causes in 2023. Out of every 100,000 live births, 50.3 Black mothers died, compared with 14.5 deaths for white people, 12.4 for Latinos and 10.7 for Asians. The NIH didn't respond to a request for comment.
Slaughter-Acey fears that the grant-cancellation signals that research and efforts to close the maternal death gap are at risk of coming to a standstill under the Trump administration. Other NIH grants that have been terminated include one that looked at prenatal exposure to public drinking water contaminants and a study that analyzed why women of color die of cervical cancer at a disproportionate rate. On Thursday, the Trump administration froze UCLA research grants from federal agencies including NIH and the National Science Foundation totaling nearly $200m, accusing the university of antisemitism and discrimination in admissions.
'It's part of a larger pattern of political interference in science that puts the health of all people at risk, especially vulnerable populations,' Slaughter-Acey said. The study 'is about understanding the root causes of poor maternal and infant health in this country – something that affects all of us, regardless of race or background. When science is silenced, communities suffer'.
Still, Slaughter-Acey and her team are hopeful that the study will continue for years to come as they search for alternative funding sources, including donations. On Slaughter-Acey's LinkedIn page, she called upon her followers to donate to the University of North Carolina Department of Epidemiology, and to include a note that they support Slaughter-Acey's work, or the name of the study, 'LIFE-2'.
'The voices of these 500 plus moms and babies should not die or be silenced with the termination of this grant,' she told the Guardian. The pull in funding 'is an example of erasure of black mothers and infants'.
There has been some temporary relief. This June, Slaughter-Acey's team received short-term funding from Michigan State University to continue their study over the next few months. Now nearly 600 moms are enrolled in the study, but without additional funding, it will probably pause again at the end of the year.
'We need research that reflects Black women's experiences'
The nearly 600 women who have joined the study were recruited from local delivery hospitals in Detroit, Michigan, in the day or two following childbirth. Slaughter-Acey chose Detroit since she completed her post-doc at the University of Michigan, where she researched the influence of social environments on Black maternal health. Participants for her study, which began in 2021, completed a post-delivery survey where they answered questions about social determinants of health including housing and food insecurity throughout their life.
Along with collecting their blood through a finger prick, researchers also collect the babies' and mothers' birth certificates from the state health department as well as the mothers' blood that was collected at birth and stored in a biobank. About 20% of the babies' grandmothers are also participating in the study by answering questions about the social environment during their pregnancies and their daughters' early childhoods.
The multilevel data collection allows the researchers to create 'this robust and triangulated dataset that includes social determinants of health, like information about food and housing insecurity', Slaughter-Acey said. 'It's capturing a more holistic view than what's been captured previously for moms in terms of maternal and infant health.'
After the moms are discharged from the hospital, the researchers also follow up with a majority of the women eight to 10 weeks after they give birth to ask about their adjustment to motherhood, whether they've received support for breastfeeding, a postpartum healthcare visit, or if they've experienced discrimination from their healthcare providers.
At the time of the funding termination, the research team was in the process of creating a 12-month postpartum checkup with the mothers to help define maternal thriving. 'When we are talking about maternal morbidity and mortality, we're defining maternal health by the absence of disease, by mom not dying, by mom not having a severe morbidity,' Slaughter-Acey said. 'But the field in general does not have a good understanding or even definition of, 'what does maternal thriving look like?' And we need to get past this conversation of maternal survival, and move to thriving.'
More than two years of funding remained in the NIH grant, during which her team had planned to recruit more mothers and to conduct data analysis. They also aimed to create a website for participants to read about the study's findings.
Related: Consent decrees force schools to desegregate. The Trump administration is striking them down
But the data that the team has analyzed thus far has revealed that mothers with a lot of adverse childhood experiences were more likely to have conflict with the father of the child. The finding, Slaughter-Acey said, 'underscores the importance of understanding how the social environment influences relationship dynamics and maybe perinatal outcomes. We know that social support is key during pregnancy'.
The team also found that one in five study participants experienced housing insecurity during their pregnancy, a factor that she said greatly affects perinatal health and is rarely documented in hospital records. They also created a tool to measure racial microagressions from healthcare providers and in the mothers' everyday life, since many in the cohort said that they experienced harmful interactions that Slaughter-Acey said may explain why they felt unsupported.
For Slaughter-Acey, the study findings 'highlight how structural inequities – across housing, healthcare, and personal history – intersect to shape maternal and infant outcomes. And they underscore why we need research that listens to and reflects the full complexity of Black women's experiences.'
NIH research funding will probably continue to take a hit under the Trump administration. A new Trump administration policy requiring that multiyear grants be paid upfront lowers the odds that a research proposal will be accepted. As a result, university labs may close.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HCA Healthcare, Inc. (HCA): A Bull Case Theory
HCA Healthcare, Inc. (HCA): A Bull Case Theory

Yahoo

time16 minutes ago

  • Yahoo

HCA Healthcare, Inc. (HCA): A Bull Case Theory

We came across a bullish thesis on HCA Healthcare, Inc. on Valueinvesting subreddit by DividendKing47. In this article, we will summarize the bulls' thesis on HCA. HCA Healthcare, Inc.'s share was trading at $334.32 as of July 25th. HCA's trailing and forward P/E were 14.04 and 13.32 respectively according to Yahoo Finance. A successful healthcare provider smiling confidently in a modern hospital facility. HCA Healthcare, the largest U.S. hospital operator, manages 190 hospitals nationwide and plans to expand further with $5.0–5.2 billion in 2025 capital expenditures to meet growing healthcare demand. Benefiting from a healthcare services industry projected to grow at a 4.9% CAGR through 2029, HCA targets raising its 27% market share to 29% by 2030. Its 2024 revenue reached $70.6 billion, with 2025 guidance of $74–76 billion, implying 6.2% growth at the midpoint, supported by $10.5 billion in free cash flow and a $140 billion enterprise value. Growth will be driven by facility upgrades, outpatient services expansion, and technological integration, including EHRs and AI-enabled diagnostics, enhancing efficiency and patient outcomes. HCA's strategic pivot toward outpatient care, alongside modernization of existing hospitals, positions it to capture an aging population's increasing needs while mitigating inpatient reimbursement risks. Consolidation trends favor HCA's acquisition-led growth, though competitive pressures from peers like Tenet Healthcare and Universal Health Services remain. A conservative DCF analysis, using a 9% WACC and 1.25% terminal growth, values the enterprise at $167 billion, with equity of $127.5 billion or $529.79 per share—representing 58.5% upside. Risks include regulatory changes, labor shortages, and public scrutiny that could pressure margins and volumes, as well as macroeconomic headwinds that may delay elective procedures. Nonetheless, HCA's scale, robust free cash generation, and focus on operational efficiency offer resilience. Even amid industry headwinds, its expansion strategy and strong positioning provide an attractive investment opportunity, with substantial upside potential underpinned by conservative growth assumptions and disciplined capital allocation. Previously, we covered a bullish thesis on Tenet Healthcare Corporation (THC) by BlackSwanInvestor in December 2024, which highlighted operational streamlining, debt reduction, and the rapid expansion of its high-margin Ambulatory Care segment. The company's stock price has appreciated by approximately 21.7% since our coverage, as the thesis played out. The thesis still stands as Ambulatory Care growth drives value creation. DividendKing47 shares a similar view but emphasizes HCA Healthcare's scale-driven expansion and capital allocation in the same healthcare services market. HCA Healthcare, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 74 hedge fund portfolios held HCA at the end of the first quarter which was 81 in the previous quarter. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.

Nootropics Depot's Tongkat Ali Declared Most Cost-Efficient and Potent in Industry, According to Independent Lab Tests
Nootropics Depot's Tongkat Ali Declared Most Cost-Efficient and Potent in Industry, According to Independent Lab Tests

Yahoo

time16 minutes ago

  • Yahoo

Nootropics Depot's Tongkat Ali Declared Most Cost-Efficient and Potent in Industry, According to Independent Lab Tests

TEMPE, Ariz., Aug. 4, 2025 /PRNewswire/ -- New independent UPLC laboratory testing has confirmed that Nootropics Depot's Tongkat Ali extracts are the industry's leading choice for both cost efficiency and potency, dramatically outpacing seven major competitors. This robust data, generated by advanced Ultra-Performance Liquid Chromatography (UPLC), positions Nootropics Depot as the category benchmark for quality and transparency in the Tongkat Ali supplement market. Key findings highlight: Nootropics Depot's 10% eurycomanone extract delivers 18.0mg of active eurycomanone per dollar, a 3.3x cost advantage over the nearest competitor and up to 40x more value than premium-priced brands. Its 10% extract provides 10–12mg of lab-verified eurycomanone per 100mg dose, while competitors typically yield only 0.13–4mg per dose. Cost per mg of eurycomanone for Nootropics Depot's 10% extract is just $0.06, compared to $0.20 to $5.77 from competitors, leading to as much as 96x more active compounds per dollar spent. These results are detailed in a transparent, third-party report and set a new standard for evidence-based supplement selection. "We've always believed the best way to earn customer trust is transparency," said Paul Eftang, CEO of Nootropics Depot. "This independent lab data is validation for consumers. Not only are we delivering more of Tongkat Ali's active compounds, we're setting the bar for value, potency, and scientific rigor in an industry notorious for marketing hype." "Consumers deserve clear, standardized information so they can make meaningful health decisions — not just clever branding and proprietary blends," Eftang added. "We invite every brand to publish their own lab results. This is how the industry should operate." Nootropics Depot offers three main Tongkat Ali options: Tongkat Ali 10% Tablets: Highest potency, delivering up to 12mg eurycomanone per 100mg dose. Tongkat Ali 2% Capsules: Full-spectrum, balanced option with 4mg per 200mg dose. Eurycomax Optimized Stack: Combines two extraction methods with synergistic ingredients for broader hormonal support. Additionally, the company's transparent and published testing methods allow consumers to easily compare products, moving the supplement industry toward higher standards of honesty and efficacy. Nootropics Depot is a leading supplement company setting benchmark standards for quality and transparency in the industry. Founded in 2013, Nootropics Depot's mission has been to educate consumers on the science behind dietary supplements, and to advance the lab testing and quality control standards of the industry. Their stance is that consumers should be able to trust the products they buy, and that the brands selling those products have a duty to ensure they are using modern validated science. Nootropics Depot offers a wide range of high-quality cognitive enhancement and general health supplements. The company's commitment to quality and transparency is evident in their rigorous testing procedures, easily accessible Certificates of Analysis (COAs), and lab testing results available on every product page. In addition, they have formed a Scientific Advisory Board with board certified doctors, PhD researchers, and botanists to ensure that consumers can trust that scientific rigor is being upheld in everything they do. Nootropics Depot's newly redesigned website features a user-friendly interface, and includes an innovative quiz to help beginners find the right supplements for their needs. With partnerships with third-party labs, and collaboration with the Future Nutra Foundation, Nootropics Depot continues to push the boundaries of supplement quality and consumer education. For more information about Nootropics Depot's products and their commitment to transparency, visit Media ContactMichael PackmanMarketing ManagerNootropics Depotmichael@ View original content to download multimedia: SOURCE Nootropics Depot Sign in to access your portfolio

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

Yahoo

time16 minutes ago

  • Yahoo

BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology

BMI OrganBank is developing novel medical devices with potential to significantly reduce the waitlist for lifesaving organ transplants, beginning with kidneys FDA Breakthrough Device Designation secures expedited FDA engagement in advance of clinical studies planned for early next year WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. "We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies" stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated "We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week." About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store